Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
argenx shares fell after the company said an independent committee found its Phase 3 UNITY study in Sjögren's disease was unlikely to meet its primary endpoint and would be discontinued. The notice says investors may submit loss details for a pending investigation.
Shares of Applied Digital Corp (NASDAQ: APLD ) rose sharply in pre-market trading after the company posted better-than-expected financial results for the first quarter. Applied Digital reported first-quarter adjusted revenue of $300.39 million, beating analyst estimates of $132.16 million, according to Pro. The digital
argenx said it will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren’s disease following an interim analysis.
argenx SE will discontinue the Phase 3 UNITY study of efgartigimod SC in Sjögren’s disease after an IDMC recommended stopping for futility at interim, with safety consistent with prior profile.